Insmed data likely supports accelerated approval in NTM, says Piper Jaffray Piper Jaffray believes Insmed's data for Arikayce in nontuberculous mycobacteria is likely to support accelerated approval, especially if the relapse rate is modest. Piper says recent data for Arikayce has caused "considerable controversy" and it reiterates an Overweight rating on shares of Insmed.
Insmed personnel strong, says Piper Jaffray After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.